Trials / Terminated
TerminatedNCT02625922
Study of the Effect of Serelaxin on High-sensitivity Cardiac Troponin I (Hs-cTnI) Release in Patients With Chronic Heart Failure
A Multicenter, Randomized, Double-blind, Crossover Placebo-controlled Phase II Study to Assess the Effect of Serelaxin Versus Placebo on High-sensitivity Cardiac Troponin I (Hs-cTnI) Release in Patients With Chronic Heart Failure After Exercise When Used in Addition to Standard of Care
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This was a multicenter, randomized, double-blind, crossover, placebo-controlled, Phase II clinical study that evaluated the effect of serelaxin versus placebo (both in addition to SoC) on the release of hs-cTnI, in patients with CHF after an exercise testing session.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Serelaxin | Serelaxin will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen |
| DRUG | Placebo | Matching placebo i.v infusion |
Timeline
- Start date
- 2016-02-05
- Primary completion
- 2017-01-11
- Completion
- 2017-01-11
- First posted
- 2015-12-09
- Last updated
- 2018-09-21
- Results posted
- 2018-09-21
Locations
9 sites across 3 countries: Germany, Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT02625922. Inclusion in this directory is not an endorsement.